About Vivostat
Vivostat is a Healthcare company based in Allerød (Denmark) founded in 2001, and was acquired by Principal Technologies in February 2024. It operates as an on-site fibrin sealant preparation systems are developed and provided. Vivostat has raised $12.89 million across 6 funding rounds from investors including European Union, Principal Technologies and EIC Fund. Vivostat offers products and services including Vivostat System, ArthroZheal, Obsidian ASG, Obsidian RFT, and Vivostat Fibrin. Its focus areas include Life Sciences, Wound Care, Medical Devices and Therapeutic Devices. Its legal entity is Vivostat A/S. Its competitors include PrognomiQ, PreOmics, LenioBio, Expedeon and List Biological Laboratories and 3 more; 6 of its 8 listed competitors have raised funding.
Company details
Vivostat was founded in 2001 in Alleroed, Denmark, and operates in the medical device sector focused on autologous blood processing. Systems for on-site preparation of fibrin sealants are developed, with the Vivostat system enabling reproducible platelet-rich plasma production without cryoprecipitation or external thrombin. The setup includes a processor for blood handling, an applicator for site-specific delivery, and disposable collection components, supporting surgical applications across clinical settings.
- Headquarters Allerød, Denmark
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website vivostat.com
- Social LinkedIn X YouTube
- Acquired by Principal Technologies (Feb 2024)
- Legal Name Vivostat A/S
- Total Equity Funding$12.89M (USD)
in 6 rounds
- Latest Funding Round$55.08K (USD), Grant
Apr 2023
- InvestorsEuropean Union
& 2 more
- Acquired byPrincipal Technologies
(Feb 2024)
Products & Services of Vivostat
Vivostat offers a comprehensive portfolio of products and services, including Vivostat System, ArthroZheal, Obsidian ASG, Obsidian RFT, and Vivostat Fibrin.
System for on-site preparation of autologous fibrin for surgery
Matrix for arthroscopic surgery to support tissue regeneration
Matrix for gastrointestinal surgery to aid healing
Matrix for fistula treatment in minimally invasive procedures
Sealant for surgical applications to promote hemostasis
Apps and channels of Vivostat
its YouTube channel Vivostat has 32 subscribers and 30 videos.
Videos from Vivostat
The most watched videos on Vivostat's YouTube channel, Vivostat (32 subscribers). Click a video to play it here.
More on Vivostat.
Funding Insights of Vivostat
Vivostat has successfully raised a total of $12.89M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $55.08 thousand completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.89M
- Total Rounds 6
- Last Round Grant — $55,079
- First Round $9.06M
(Feb 2007)
- Investors Count 2
All 6 funding rounds of Vivostat with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | $55,079 | Grant | – | – | |
| May 2021 | $2.57M | Grant | – | – | |
| Apr 2020 | $54,286 | Grant | – | – | |
| Dec 2019 | $55,095 | Grant | – | – | |
| Feb 2009 | $3.83M | Series A | – | – | – |
| Feb 2007 | $9.06M | Series A | – | – | – |
3 investors in total: 3 institutional.
Investors in Vivostat
Vivostat has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Principal Technologies and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Healthcare investments are targeted by Principal Technologies private equity fund. | – | principal-technologies.com | Vancouver, Canada | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Vivostat
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Vivostat
4 dated milestones of Vivostat across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Vivostat is founded.
- Funding First funding round of $9.1M.
- Funding Latest funding round, Grant, of $55K.
- Exit Acquired by Principal Technologies.
Competitors of Vivostat
Vivostat has 8 listed competitors in our database, 6 of them funded. They include PrognomiQ, PreOmics, LenioBio, Expedeon and List Biological Laboratories, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prognomiq.com | 2020 | San Mateo, United States | $90.36M | 24 | Developer of tests for the detection and treatment of cancer and other diseases | |
| preomics.com | 2014 | Munich, Germany | $19.14M | 22 | Reagents and instruments for proteomics research are supplied by PreOmics. | |
| leniobio.com | 2016 | Dusseldorf, Germany | $13.01M | 18 | Kits for cell-free eukaryotic protein expression are provided. | |
| expedeon.com | 2003 | Swavesey, United Kingdom | $390,000 | 1,587 | Reagents and kits for protein-based research are developed and supplied. | |
| listlabs.com | 1978 | Campbell, United States | $48.4M | – | Specializes in the production of research reagents | |
| mjbiopharm.com | 2002 | Mumbai, India | $9.13M | 265 | Animal and human rDNA Insulin products and dosage forms | |
| acrobiosystems.com | 2016 | Newark, United States | – | 22 | Recombinant proteins are manufactured to support cancer immunotherapy efforts. | |
| anshlabs.com | 2010 | Webster, United States | – | 33 | Immunoassay reagents and kits are developed for life science research. |
Detailed competitors of Vivostat
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Wound Care
10 companies that operate in the same segment as Vivostat (Wound Care), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Developer of advanced haemostat and wound care dressing products | 2008 | Ahmedabad, Gujarat, India | USD 42.71 M | USD 2.88 M | 70 | |
Oxygen-based wound therapy devices are developed for healing non-healing wounds. | 2003 | Waterbeach, Cambridgeshire, United Kingdom | USD 68.39 M | – | – | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M | – | – | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Cold plasma solutions for wound treatment are developed. | 2013 | Eindhoven, Noord-brabant, Netherlands | USD 7.06 M | – | – | |
Point-of-care devices for wound bacterial assessment are provided. | 2013 | Toronto, Ontario, Canada | USD 43.2 M | – | 49 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vivostat
Complete news archive for Vivostat
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vivostat
Vivostat was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Vivostat is headquartered in Allerød, Denmark.
Vivostat is a funded company, having raised a total of $12.89M across 6 funding rounds to date. The company's 1st funding round was a Series A of $9.06M, raised on Feb 2007.
Vivostat was founded in 2001 in Alleroed, Denmark, and operates in the medical device sector focused on autologous blood processing. Systems for on-site preparation of fibrin sealants are developed, with the Vivostat system enabling reproducible platelet-rich plasma production without cryoprecipitation or external thrombin. The setup includes a processor for blood handling, an applicator for site-specific delivery, and disposable collection components, supporting surgical applications across clinical settings.
Vivostat offers Vivostat System, ArthroZheal, Obsidian ASG, Obsidian RFT, and Vivostat Fibrin.
Vivostat has 3 investors. Key investors include European Union, Principal Technologies, and EIC Fund.
Vivostat operates through Vivostat A/S.
Yes. Vivostat was acquired by Principal Technologies in February 2024.